Catatan episode
In this episode, we review the 2026 Consensus Statement algorithm for metabolic dysfunction associated steatotic liver disease (MASLD) management in adults with type 2 diabetes. Topics include the epidemiology and diagnosis of MASLD, progression to metabolic dysfunction associated steatohepatitis (MASH), lifestyle interventions and weight loss goals, the role of resmetirom, GLP-1 receptor agonists, tirzepatide, pioglitazone, and SGLT2 inhibitors, and practical evidence based strategies to improve liver health and reduce cardiovascular, renal, and hepatic complications.
Situs: podcasters.spotify.com

